In 2011 Bayer HealthCare Pharmaceuticals agreed with the World Health Organization (WHO) to support countries in the treatment of multidrug-resistant tuberculosis (MDR-TB) with moxifloxacin, a well-known antibiotic for the treatment of acute respiratory infection as well as other infections with an established safety record.
The collaboration with the WHO includes the involvement in a program designed to support increased access to quality-assured second-line anti-tuberculosis which targets to increase treatment success against MDR-TB and thereby could also reduce the likelihood for further resistance development to anti tuberculosis drug.
STOP TB partnership of the WHO makes moxifloxacin available to MDR TB patients in need under specifically defined conditions of treatment programs authorized by the STOP-TB Partnership in collaboration with national TB treatment programs.
Summary of impact through December 2013 and forward looking information
Sixteen countries have joined the program since December 2011. A total of around 1.3 million moxifloxacin tablets were supplied to six countries (China, Georgia, Armenia, Haiti, Russia and Indonesia) in 2013. This quantity of the drug enables the treatment of a good 2,450 MDR-TB patients for the minimum treatment period of 18 months.
|Location||East Asia and Pacific, Venezuela, Ukraine, South Africa, Russian Federation, Philippines, Peru, Mexico, Indonesia, India, Haiti, Georgia, Ecuador, Cuba, China, Belarus, Armenia, Southern Africa, South Asia, Latin America and Caribbean, Eastern Europe, Central Asia, Central Africa|